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The aim of the study was to compare the behavior of seeded 
cells on synthetic and natural aortic valve scaffolds during 
a low-flow conditioning period. Polyurethane (group A) and 
aortic homograft valves (group B) were consecutively seeded 
with human fibroblasts (FB), and endothelial cells (EC) using a 
rotating seeding device. Each seeding procedure was followed 
by an exposure to low pulsatile flow in a dynamic bioreactor 
for 5 days. For further analysis, samples were taken before 
and after conditioning. Scanning electron microscopy showed 
confluent cell layers in both groups. Immunohistochemi-
cal analysis showed the presence of EC and FB before and 
after conditioning as well as the establishment of an extracel-
lular matrix (ECM) during conditioning. A higher expression 
of ECM was observed on the scaffolds’ inner surface. Real-
time polymerase chain reaction showed higher inflammatory 
response during the conditioning of homografts. Endothelial-
ization caused a decrease in inflammatory gene expression. 
The efficient colonization, the establishment of an ECM, and 
the comparable inflammatory cell reaction to the scaffolds 
in both groups proved the biocompatibility of the synthetic 
scaffold. The newly developed bioreactor permits condition-
ing and cell adaption to shear stress. Therefore, polyure-
thane valve scaffolds may offer a new option for aortic valve 
replacement. ASAIO Journal 2013;59:309–316.
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Cardiovascular diseases are currently the major cause of 
death. With the growing global population and the increasing 
life expectancy, this problem will continue to grow. The num-
ber of patients requiring heart valve surgery will increase from 
290,000 in 2003 to 850,000 in 2050.1
Currently, there are two different types of heart valve pros-
theses in use: mechanical and biological implants. Both types 
of implants offer the possibility to recover the normal valve-
function, but unfortunately with a large number of limitations. 
On the one hand, mechanical prostheses require life-long oral 
anticoagulation therapy,2 and on the other hand, the lifetime 
of the biological prostheses is limited.3 Therefore, it is neces-
sary to develop a new kind of heart valve whose properties 
do not include the most critical disadvantages of the currently 
available prostheses. The development of a tissue engineered 
heart valve seems to be the most promising way: “Advantages 
of an engineered tissue heart valve would likely include non-
thrombogenicity, infection resistance, and cellular viability.”4
The field of tissue engineering has the aim of restoring dis-
eased organs or lost functions by a combination of cells with 
scaffolds.5 Heart valve tissue engineering attempts, by an intel-
ligent combination of these resources, to develop prostheses 
with a high durability and an inert surface, concerning coag-
ulation. At the moment, three different approaches are used 
by research groups to achieve this aim. One possibility is the 
development of tissue engineered heart valves based on biode-
gradable scaffolds.6 The application of decellularized biologi-
cal valves presents the second possibility.7 The development 
of a third cell-based option by using nondegradable scaffold 
materials is also under investigation.
The aim of the study was to compare new synthetic poly-
urethane (PU) scaffolds (group A) with conventional cryo-
preserved/thawed aortic homograft valves (group B) under 
analogous conditions in a newly developed bioreactor. Group 
B was used as a control group. The main interest was to study 
the reaction of seeded cells on variable materials to low flow 
shear stress after a short resting period of 24 hours.
Material and Methods
Cell Isolation and Cultivation
Saphenous vein segments, leftover from bypass operations, 
were used for vascular cell isolation. The study was 
approved by the Ethics Committee of Ludwig-Maximilian 
University Munich and before operation, patients gave 
their written informed consent for the use of their venous 
cells. Cells were isolated according to previously published 
methods.8 However, collagenase was replaced with trypsin/
ethylenediaminetetraacetic acid (EDTA) solution (10×; 
Sigma–Aldrich GmbH, Taufkirchen, Germany) to preserve the 
remaining fibroblast (FB) cell layer. First, the vein segments 
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were cannulated and rinsed with 500 ml M199 (Biochrom 
AG, Berlin, Germany) supplemented with 1 ml heparin (5000 
i.E.; ratiopharm GmbH, Ulm, Germany) and 5 ml gentamycin 
(10 mg/ml; invitrogen AG, Darmstadt, Germany). For 
endothelial cell (EC) isolation, the segments were filled with 
trypsin/EDTA solution and incubated for 25 minutes at 37°C. 
For FB isolation, the segments were incubated for 30 minutes at 
37°C with 20 mg collagenase solved in 10 ml of human serum 
albumin (200 g/L; Baxter GmbH, Unterschleißheim, Germany). 
The obtained cells were initially cultivated in 12.5 cm2 culture 
flasks in EC growth medium (ECGM; Promocell GmbH, 
Heidelberg, Germany) supplemented with 6% fetal calf 
serum (Lonza GmbH, köln, Germany) and 0.2% penicillin/
streptomycin (Sigma–Aldrich GmbH, Hamburg, Germany) 
and FB growth medium (FGM; Promocell GmbH, Heidelberg, 
Germany) supplemented with 11% fetal calf serum and 0.2% 
penicillin/streptomycin, respectively. Medium was changed 
every 2–3 days. Cells were passaged at confluency.
Scaffolds
Polyurethane valves (group A, n = 4; Figure 1A) and homo-
grafts (group B, n = 4; Figure 1B) were used as scaffolds for the 
development of a new tissue engineered heart valve.
Polyurethane scaffolds. Polyurethane scaffolds with a di-
ameter of 24 mm were manufactured by a spraying technique 
(patent DE 28 06 030 C2). randomly oriented PU fibers were 
measured to have a median diameter of 1.55 μm (Figure 3A). 
The fibers formed a sheet with a thickness of 0.3 mm. Surface 
modification was not realized for the cell-seeding procedure. 
For seeding purpose, PU scaffolds were sent to a certified 
sterilization supplier and were γ-sterilized at 10 kGy. For safe 
handling, the scaffolds were fixed to a special Teflon (Sahlberg 
GmbH&Co. kG, Munich, Germany) mounting (Figure 1C) by 
a continuous circular suture using a surgical thread (Suprolene 
3/0, resorba GmbH, Nürnberg, Germany) prior to cell seed-
ing. The mounting was designed for application in the seeding 
device and the conditioning bioreactor.
Homografts. Heart valve donors had an average age of 
52.25 ± 5.74 years at the date of explantation. Exclusion criteria 
for the experiment were any signs of insufficiency or any mac-
roscopic damage. Average storage time was 7.33 ± 2.11 years. 
Cryopreservation of the homografts was performed according 
to previously published methods.9 Scaffolds with a diameter of 
27 mm were thawed in ringer solution at 56°C and washed in 
Earle’s M199 (Biochrom AG, Berlin, Germany) for 2 hours at 
room temperature (rT). Homografts were sutured to the Teflon 
mounting (Figure 1C) by single stitches using a surgical thread 
(Suprolene).
Cell Seeding and Conditioning
For better endothelialization results, the scaffolds were 
pre-seeded with FB, followed by colonization with EC. 
The seeding procedure using a 3D rotating seeding device 
(Figure 2A) was performed as previously described.9,10 Briefly, 
92.11 ± 11.08 × 106 FB (difference of counted cells in the 
suspension before and after seeding procedure) in 100 ml 
supplemented FGM were dynamically seeded onto the native 
scaffolds for 24 hours (running phase: 2.5 minutes; holding 
phase: 30 minutes). Gas exchange was ensured by a silicone 
membrane. After FB seeding, the scaffolds were transferred to a 
glass bin containing 200 ml fresh supplemented FGM and were 
cultured for 24 hours under static conditions. in the following 
5 days, the valves were incubated in a novel self-made 
conditioning bioreactor (EU-Patent pending: EP10166094.2; 
Figure 2B).11 During this period, the valves were perfused with 
400 ml supplemented FGM by an increasing sinusoidal pulsatile 
flow for 48 hours at 750 ml/min (≈24 bpm) and 72 hours at 
1100 ml/min (≈35.5 bpm). Half of the supplemented FGM was 
exchanged after 2 days. The conditioning period was followed 
by a second seeding procedure for the EC (96.48 ± 8.05 × 106 
cells). The EC seeding, the subsequent second resting period, 
and the final conditioning procedure were performed as 
described for FB; however, supplemented ECGM was used 
for cell nutrition. The performance of the valve leaflets was 
controlled and documented using an endoscope (Figure 2B5).
Figure 1. A: Sprayed polyurethane (PU) scaffold, diameter: 24 mm, group A (n = 4). B: Cryopreserved/thawed homograft, diameter: 27 mm, 
group B (n = 4). C: Teflon mounting for valve fixation in the seeding device and the conditioning bioreactor. Valves were fixed with a surgical 
thread in a continuous suture technique (polyurethane), respectively, single stitches (homograft).
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Evaluation Methods
Scanning electron microscopy (SEM), immunohistochemis-
try (iHC), and real-time polymerase chain reaction (PCr) were 
used for evaluation. Samples were taken from veins, cell cul-
tures, and native scaffolds, before and after each processing 
step. After the second conditioning period, samples were taken 
from the supravalvular, valvular, and subvalvular region of the 
aortic wall as well as from the valvular cusps.
SEM evaluation. For this procedure, the samples were 
fixed in a solution of 456 ml aqua bi-distilled (Ampuwa, 
Fresenius kabi Deutschland GmbH, Bad Homburg v.d. H., 
Germany), 0.75 ml 1 N hydrochloric acid (Titrisol, Merck 
kGaA, Darmstadt, Germany), 43.5 ml glutaraldehyde, and 
5.65 gm sodium cocodylate trihydrate (Sigma–Aldrich Chemie 
GmbH, Steinheim, Germany) at 4°C for a minimum of 48 
hours. Subsequently, they were dehydrated by an ascending 
ethanol series (30, 50, 70, and 96%) and 100% acetone (Merck 
kGaA, Darmstadt, Germany), followed by critical point dry-
ing and gold sputtering (28 mA; 570 V) of 180 s at 10−5 mbar. 
A “Zeiss Evo LS 10” (Carl Zeiss AG, Oberkochen, Germany) 
scanning electron microscope was used for microscopy and 
documentation.
IHC analysis. in iHC evaluation, an indirect staining meth-
od was used. After at least 3 days of fixation time in a for-
malin solution (roti-Histofix 4%, Carl roth GmbH, karlsruhe, 
Germany), the samples were embedded in paraffin and sec-
tioned with a thickness of 10 μm. in a few interim stages, the 
paraffin was washed out, the cell membrane was permeabi-
lized, and the antigens were unmasked. Samples were incu-
bated for 16 hours at 4°C with monoclonal mouse antibod-
ies (AB) against cluster of differentiation (CD)31 (dilution: 
1:30; Dianova GmbH, Hamburg, Germany), Human Thymic 
Fibroblasts Antibody (TE)-7 (0,1 mg/ml; Chemicon-Millipore 
GmbH, Schwalbach, Germany), smooth muscle cell (SMC)-
myosin (954 mg/L; DakoCytomation, Hamburg, Germany), 
α-actin (44 mg/L; DakoCytomation), vascular endothelial 
(VE)-cadherin/CD144 (0.2 mg/ml; Beckman Coulter GmbH., 
krefeld, Germany), connexin-43 (1 mg/ml; Chemicon-Millipore 
GmbH), fibronectin (0.6 mg/ml; Sigma–Aldrich GmbH), inter-
cellular adhesion molecule (iCAM; clone: W-CAM-1; dilu-
tion: 1:20; Chemicon-Millipore GmbH), CD106 (200 μg/ml; 
Thermo Fisher Scientific GmbH, Dreieich, Germany), and col-
lagen iV (5.4 mg/ml; Sigma–Aldrich GmbH). in the following 
step, the samples were incubated for 30 minutes at rT with 
the second AB (Dual Link System-HrP, Dianova GmbH). This 
horseradish-peroxidase-linked AB allowed the visualization of 
the AB complexes. Furthermore, nuclear counter staining with 
Mayer’s hemalum solution (Merck, Darmstadt, Germany) was 
performed.
PCR evaluation. Samples, stored in liquid nitrogen, 
were used for the rNA isolation using rNeasy Plus Mini kit 
(Qiagen GmbH, Hilden, Germany) according to the manu-
facturer’s protocol. The purity and quantity of the rNA were 
measured by photometry (BioPhotometer, Eppendorf AG, 
Hamburg, Germany). reverse transcription (QuantiTect 
reverse Transcription kit, Qiagen GmbH) was performed ac-
cording to Qiagen protocol. For PCr, a rotor-Gene Q 2plex 
System (Qiagen GmbH) with SYBr Green detection was 
used. To determine the primer concentration, a dilution se-
ries (1:5, 1:10, 1:100, 1:1000, 1:10000) for standard curve 
graphing was compiled. During measurement, 35 replication 
cycles were performed, including, respectively, one negative 
control using water instead of the primer. Temperatures of 
95°C (10 seconds) in the denaturation phase and 60°C (30 
seconds) in the replication phase were used. The expressions 
of interleukin (iL)-1a (QuantiTect Primer Assay iL-1a, Qiagen 
GmbH), iL-6 (QuantiTect Primer Assay iL-6, Qiagen GmbH), 
iL-8 (QuantiTect Primer Assay iL-8, Qiagen GmbH), monocyte 
chemotactic protein (MCP)-1 (QuantiTect Primer Assay CCL2, 
Qiagen GmbH), vascular cell adhesion molecule (VCAM; 
QuantiTect Primer Assay VCAM, Qiagen GmbH]), and glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH; QuantiTect 
Primer Assay GAPDH, Qiagen GmbH) were measured. The 
obtained Ct-values were normalized to the housekeeping gene 
GAPDH. The specificity of the PCr products was checked by 
melting curve analysis (from 60–90°C; +1°C/10 sec) and gel 
electrophoresis (FlashGel System, Lonza GmbH, Cologne, 
Germany). 
All values are expressed as means ± standard deviation. Stu-
dent’s t-test was performed for comparison of data; the prob-
ability value p < 0.05 was considered significant.
Figure 2. A: Bioreactor for 24 hours 3D cell seeding (running phase = 2.5 min, holding phase = 30 min).10 B: Bioreactor for 5 day condition-
ing period11 (750–1100 ml/min). B1: Mounting with polyurethane scaffold placed in the incubation chamber filled with 400 ml culture medium 
during the experiment. B2: Silicone membrane for conduction of pulsatile movement to the culture medium. B3: Piston for generation of 
pulsatile movements. B4: Electronic motor with eccentric piston rod. B5: Endoscope for the monitoring of valve performance.
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Results
Topography of the Scaffolds Surface
SEM analysis was performed to assess the topography of 
the cell layer. The recordings showed an uneven, abrasive 
but homogenous surface in the native samples of both groups 
(Figure 3, A and B). The structure of the sprayed randomly 
orientated PU fibers (group A) was clearly visible (Figure 3A).
After FB seeding procedure, a nearly confluent cell layer was 
visible in both groups. On homograft surfaces at few positions, 
the cells were not clearly identifiable. Overall, the surface 
appeared smoother and in group A, the PU fibers were com-
pletely covered with cells. Partially the fusiform shape of the 
FB was recognizable (Figure 3, C and D).
The structure of the surface in both groups seemed to be 
changed after cellularization with EC. The seeded endothelial 
layer appeared as a cobblestone surface. in group A, a totally 
confluent cell layer was visible (Figure 3E). in group B, a nearly 
confluent cell layer was observable; however, several small 
unseeded regions were noticeable (Figure 3F).
At the end of the second conditioning period, the samples 
showed a slightly different sight. On several spots the surface 
of the conditioned homografts seemed lacerated (Figure 3H, 
arrows). in group A, a few PU fibers were visible. However, 
nearly the entire surface was covered with a cobblestone-like 
Figure 3. A: Native samples of polyurethane (PU) scaffolds dem-
onstrated randomly orientated fibers with a median diameter of 1.55 
μm. B: Native samples of the homografts showed an abrasive sur-
face with some cell fragments. C: Complete coverage of the PU 
fibers after fibroblasts (FB) seeding. The typical fusiform shape of 
FBs is recognizable. D: Smooth and homogenous surface after FB 
seeding due to a complete coverage of the scaffold. E: Endothelial 
cell (EC) seeding of PU scaffolds resulted in a confluent cellular cov-
erage with the characteristic cobblestone pattern. F: EC seeding of 
the homografts also generated a confluent EC layer. The fissures 
found on the scaffold are dehydration artifacts. G: A cobblestone-
like relief indicates a confluent endothelial lining of PU scaffolds 
after the second conditioning period. H: Homografts were also 
covered with EC after conditioning. A few areas revealed marginal 
damage (black arrows); samples C, D, E, and F were taken after 
the resting period (24 h after conditioning). Samples G and H were 
taken directly after the second conditioning period; scale bars: A = 
20 μm, B–H = 150 μm.
Figure 4. After fibroblasts (FB) seeding, TE-7 staining displayed 
a compact and confluent FB layer on polyurethane (PU) scaffolds 
(A; arrows); and a thin cell layer on homografts (B; arrows); staining 
against CD31 revealed successful endothelial cells (EC) seeding on 
PU scaffolds (C; arrows) and on homografts (D; arrows). After the 
final conditioning period, confluent cell layers of FB were detected 
on PU (E1; arrows) and on homografts (F1; arrows) by staining 
against TE-7. The presence of EC on the surface of the PU (E2; 
arrows) and of the homografts (F2; arrows) was demonstrated by 
CD31 staining. The establishment of a distinct extracellular matrix 
during the second conditioning period was found by positive stain-
ing against Collagen IV on polyurethanes (G; arrows) and homo-
grafts (H; arrows). Cell nuclei were stained with hemalaun (purple); 
scale bars: 300 μm. CD, cluster of differentiation; TE, human thymic 
fibroblasts antibody.
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cell layer (Figure 3G). The cusps were completely coated with 
a continuous cell layer.
Protein Expression
The presence of EC and FB in the respective cell cultures 
was displayed by staining against CD31 (EC antibody) and TE-7 
(FB antibody). Cell nuclei were stained with hemalaun (A–H 
purple). The native samples of group B showed no superficial 
cell layer stainable by hemalaun, but some positive reactions 
in the internal space of the scaffold wall. Additionally, staining 
against fibronectin and collagen iV (extracellular matrix [ECM] 
specific) evoked a strong reaction.
Staining of FB-seeded scaffolds displayed a moderately posi-
tive reaction of TE-7 AB, pointing to a successful FB seeding 
procedure (Figure 4, A and B; arrows). iCAM and α-actin ABs 
also showed a lightly positive reaction (Table 1). The moderately 
positive reaction of CD31 AB (Figure 4, C and D; arrows) after 
the EC seeding procedure suggested successful seeding of EC 
in both groups. iCAM and collagen iV expression increased, as 
shown by a stronger staining reaction (Table 1). Strong positive 
peroxidase reactions in the staining against TE-7 and CD31 of 
both groups after the second conditioning procedure confirm 
the unchanged presence and integrity of the FB and EC layers, 
respectively (Figure 4, E1, E2, F1, F2; arrows). An enhance-
ment of ECM and cellular adhesion after the EC conditioning 
period was detected by a strong, intensified positive reaction of 
α-actin, VE-cadherin, fibronectin, iCAM, and collagen iV (Fig-
ure 4, G and H, arrows; Table 1). A higher expression of ECM 
was observed on the scaffold’s inner surface.
Gene Expression
Figure 5 demonstrates the mean values of gene expres-
sion before and after the conditioning period of FB-seeded as 
well as FB- and EC-seeded PU valves and homografts, respec-
tively. Gene expression was normalized to the expression 
of the housekeeping gene GAPDH. The analysis of different 
segments of the heart valves (aortic wall and cusps) in both 
groups showed equivalent gene expressions for all cytokines 
and chemokines.
iL-1a and VCAM presented a negligible expression in both 
groups during the whole experiment. Negligible pro-inflam-
matory gene expression change of iL-6 (−1.12%) was detected 
while the seeded FB layer in Group A (Figure 5A) was con-
ditioned, whereas the level of iL-8 gene expression decreased 
(−59.48%) and an increase of MCP-1 (+138.78%, p < 0.05) was 
detected during the conditioning of FB in group A. An increase 
in the expression of most genes was observed (iL-6: +122.61%; 
iL-8: +454.38%; MCP-1: +45.39%) in group B (Figure 5B).
in both groups, the endothelialization caused a decrease in 
inflammatory cell response (group A, Figure 5A: iL-6: −78.82%; 
MCP-1: −68.71%; group B, Figure 5B: iL-6: −97.42%; 
iL-8: −67.01%; MCP-1: −89.44%, p < 0.05). For iL-8 in group 
A only, an increase of +559.7% (p < 0.05) was observed. 
Nonetheless, iL-8 expression after endothelialization is slightly 
lower than that in group B.
During the second conditioning step of the scaffold colo-
nized with FB and EC, a slight decrease in iL-8 (group A, Figure 
5A: −66.23%; group B, Figure 5B: −13.98%) was observed. 
iL-6- and MCP-1 expression was approximately on the same 
level in this period.








After EC  
ConditioningEC FB
Group A
 CD 31 +++ 0 ND 0 +++ +++
 TE-7 0 +++ ND ++ + +++
 SMC-myosin ND ND ND 0 0 0
 α-actin ND ND ND + + +++
 VE-cadherin ND ND ND + + +++
 Connexin-43 ++ ND ND 0 + +
 Fibronectin ND +++ ND + + +++
 ICAM ND ND ND + ++ +++
 CD 106 ND ND ND 0 0 +
 Collagen IV ND ++ ND + ++ +++
Group B
 CD 31 +++ 0 0 0 ++ ++
 TE-7 0 +++ 0* +* ++* ++*
 SMC-myosin ND ND 0* 0* 0* +*
 α-actin ND ND 0* +* +* ++*
 VE-cadherin ND ND 0 0 + ++
 Connexin-43 ++ ND 0 + + +
 Fibronectin ND +++ 0* 0* +* +++*
 ICAM ND ND 0* +* ++* ++*
 CD 106 ND ND 0 0 0* +*
 Collagen IV ND ++ 0* 0* +* +++*
0 denotes no staining visible; +, light staining; ++, moderate staining; +++, strong staining.
*Positive reaction on scaffold material.
CD, cluster of differentiation; EC, endothelial cells; FB, fibroblasts; ICAM, intercellular adhesion molecule; IHC, immunohistochemistry; ND, 
not done; SMC, smooth muscle cell; TE, human thymic fibroblasts antibody; VE, vascular endothelial.
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Discussion
The mean age of patients requiring cardiac valve replacement 
increases every year.12 Therefore, the most beneficial form of 
therapy seems to be the extraction and the use of adult cells 
with good cultivation characteristics for the manufacturing of 
a tissue engineered heart valve. it has already been described 
that cells of aortic valvular origin appear as one of the most 
suitable cell types for aortic valve tissue engineering; however, 
there is no reasonable mode of autologous application.13 On 
the other hand, cell source comparisons, also performed in our 
department,14 have shown excellent results for cells isolated 
from saphenous vein segments.15,16 Corresponding to these 
results, a specific isolation of EC and FB from saphenous vein 
segments was possible, a good replication rate in cell culture 
enabled a fast usage, and good conditioning attributes were 
observed. Considering these arguments, this cell source seems 
to be a good consensus concerning a practicable harvesting 
and the creation of a durable and viable tissue engineered 
aortic valve for an autologous application.
in the choice of the scaffold, several reasons militated for 
taking a nondegradable material, such as PU, for a tissue 
engineered aortic heart valve. Polyurethane is known as one 
of the most bio- and hemocompatible materials used in the 
development of medical devices.17 However, aging of PU has 
been found to be a possible drawback of this material in clini-
cal studies. Nevertheless, its degradation rate is significantly 
lower than that of most degradable materials used for tissue 
engineering applications (e.g., polyglycolic acid and polylac-
tic-coglycolic acid).18,19 Another reason against degradable 
scaffolds is the high pressure stress in aortic position, mean-
ing that proper function and a high life expectancy cannot be 
guaranteed.20,21 Under these conditions, just decellularized 
homografts showed a promising in vivo short- and mid-term 
performance.22–24 Baraki et al.23 showed in their comparison 
between decellularized homografts and a native control group 
that the decellualrized valves had even a better outcome con-
cerning morphology and function after 9 months in systemic 
circulation. A drawback of this kind of scaffold is, however, 
the limited availability of homografts.25 Up to now, synthetic 
degradable materials proved their qualification only in pulmo-
nary arterial position.6 The uncontrollable absorbability and 
the possible inflammatory reaction during the resorption time 
are additional arguments against biodegradable materials.4,26
Figure 5. Cyto- and chemokine expressions of fibroblast and fibroblast-endothelial cell seeded scaffolds before (BC) and after condition-
ing (AC) A: Gene expression of interleukin (IL)-6, IL-8, and monocyte chemotactic protein (MCP)-1 in cells seeded onto polyurethane valves: 
fibroblasts (FB) conditioning induced a decrease in IL-8 and an increase in MCP-1 expression. IL-6 expression remained at a constant level. 
The endothelialization step caused decrease in IL-6 and MCP-1 expression. Measured IL-8 increased in this step, which regresses in the fol-
lowing conditioning step. For IL-6 and MCP-1 no significant change was observed during endothelial cell (EC) conditioning. B: Gene expres-
sion of IL-6, IL-8, and MCP-1 in cells seeded on homografts: conditioning of FB causes an increase of the gene expression of IL-6, IL-8, 
and MCP-1, which is regressive after EC seeding. EC conditioning does not cause a significant change in gene expression. No significant 
difference was found between the gene expression of cells in aortic walls and cusps in either group; samples were taken directly BC and AC 
periods; values are normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
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The untreated cryoconserved/thawed homografts, which are 
established prostheses in modern heart surgery, were used as a 
control group in our study. in this way, it was possible to com-
pare the behavior of seeded cells on native tissue and synthetic 
scaffold. The absence of endothelial and interstitial cells on 
native homografts surface, shown by negative CD31- and HE-
staining results, could be explained by the cryopreservation 
process. Confirming these results, Lupinetti et al.27 showed that 
cryopreservation of homografts can result in a severe loss of 
EC coverage.
in all experiments, both scaffold materials showed an 
adequate cell-seeding efficiency and presented a nearly 
completely confluent FB cell layer on the surface. The already 
described preseeding with FB resulted in a good subsurface 
for a confluent EC layer with good cell adherence.12 The 
achieved intact endothelial surface plays a decisive role for 
the avoidance of the anticoagulation therapy in a following 
in vivo use.2 Additionally, the endothelialization caused a 
desirable decrease in iL-6 and MCP-1 gene expression in both 
groups. Due to the known importance of these cytokines and 
iL-8 on inflammatory reaction, a downregulation in a target-
cell-free surrounding is crucial.28,29 A low inflammatory cell 
response plays in vivo a decisive role in the healing process 
after a heart valve implantation and the long-term functionality 
of a bio-prosthetic valve.30 However, iL-8 is also known as 
a pro-proliferative, a pro-angiogenic, and anti-apoptotic 
cytokine.31,32 This might explain the persistent expression after 
endothelialization and during the second conditioning period.
An essential component of each tissue is a specific ECM.33 
To provoke the establishment of an ECM by the seeded cells 
of a tissue engineering construct, an appropriate stimulus is 
necessary. in cardiovascular tissue engineering, Jockenhoevel 
et al.34 and other research groups showed that flow-depending 
mechanical stress induces ECM formation.35 in line with these 
results, the establishment of an ECM and the habituation of 
the cells were observed during the 5-day conditioning peri-
ods, demonstrated by positive staining against collagen iV and 
fibronectin. An increased ECM growth on scaffolds’ inner/flow 
surface proved the flow dependence. The major construction 
of the ECM was observed during EC conditioning and due 
to the increased inflammatory influence, the first condition-
ing period did not appear to be beneficial. Additionally, the 
desired effect of downregulation of chemotactic factors, such 
as iL-8 and MCP-1,29 was mainly observed after endothelial-
ization. So, longer resting periods and longer EC conditioning 
for a further decrease in inflammatory cell reaction and less 
possible arteriosclerotic effects should be investigated.36
The PU scaffold showed a good cell-seeding efficiency and 
provoked no higher, or even a lower, inflammatory cell reaction 
during the whole experiment. The endothelialization results 
were similar in the control group (group B). in summary, the 
PU scaffolds proved their good biocompatibility. Our condi-
tioning bioreactor allowed the cells to adapt to shear stress by 
establishing a strong ECM. At this point, these results cannot yet 
be transferred to the in vivo environment; however, the results 
have suggested that the polymer-based scaffold is a good can-
didate for this step. Thus this new tissue engineered heart valve 
may offer a new option for aortic valve replacement surgery.
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